Try a new search

Format these results:

Searched for:

in-biosketch:true

person:segevd01

Total Results:

1179


Motivations and outcomes of compatible living donor-recipient pairs in paired exchange

Chipman, Valerie; Cooper, Matthew; Thomas, Alvin G; Ronin, Matthew; Lee, Brian; Flechner, Stuart; Leeser, David; Segev, Dorry L; Mandelbrot, Didier A; Lunow-Luke, Tyler; Syed, Shareef; Hil, Garet; Freise, Chris E; Waterman, Amy D; Roll, Garrett R
Increasing numbers of compatible pairs are choosing to enter paired exchange programs, but motivations, outcomes, and system-level effects of participation are not well described. Using a linkage of the Scientific Registry of Transplant Recipients and National Kidney Registry, we compared outcomes of traditional (originally incompatible) recipients to originally compatible recipients using the Kaplan-Meier method. We identified 154 compatible pairs. Most pairs sought to improve HLA matching. Compared to the original donor, actual donors were younger (39 vs. 50 years, p < .001), less often female (52% vs. 68%, p < .01), higher BMI (27 vs. 25 kg/m², p = .03), less frequently blood type O (36% vs. 80%, p < .001), and had higher eGFR (99 vs. 94 ml/min/1.73 m², p = .02), with a better LKDPI (median 7 vs. 22, p < .001). We observed no differences in graft failure or mortality. Compatible pairs made 280 additional transplants possible, many in highly sensitized recipients with long wait times. Compatible pair recipients derived several benefits from paired exchange, including better donor quality. Living donor pairs should receive counseling regarding all options available, including kidney paired donation. As more compatible pairs choose to enter exchange programs, consideration should be given to optimizing compatible pair and hard-to-transplant recipient outcomes.
PMID: 34467618
ISSN: 1600-6143
CID: 5127592

After 20 Years of Advocacy, Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Finally Become Law

Levan, Macey L; Reich, David J; Segev, Dorry L L
PMCID:8678179
PMID: 34342961
ISSN: 1534-6080
CID: 5127472

Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series [Letter]

Connolly, Caoilfhionn M; Chiang, Teresa Po-Yu; Boyarsky, Brian J; Ruddy, Jake A; Teles, Mayan; Alejo, Jennifer L; Massie, Allan; Werbel, William A; Shah, Ami A; Christopher-Stine, Lisa; Garonzik-Wang, Jacqueline; Segev, Dorry L; Paik, Julie J
PMID: 34556484
ISSN: 1468-2060
CID: 5127672

The Clinical and Economic Benefit of CMV Matching in Kidney Transplant: A Decision Analysis

Axelrod, David; Chang, Su-Hsin; Lentine, Krista L; Schnitzler, Mark A; Norman, Doug; Olyaei, Ali; Malinoski, Darren; Dharnidharka, Vikas; Segev, Dorry; Istre, Gregory R; Lockridge, Joseph B
Background/UNASSIGNED:The development of cytomegalovirus (CMV) infection after kidney transplant remains a significant cause of posttransplant morbidity, graft loss, and mortality. Despite appropriate antiviral therapy, recipients without previous CMV exposure can currently be allocated a kidney from a donor with previous CMV infection (D+R-) which carries the greatest risk of posttransplant CMV infection and associated complications. Preferential placement of CMV D- organs in negative recipients (R-) has been shown to reduce the risk of viral infection and associated complications. Methods/UNASSIGNED:To assess the long-term survival and economic benefits of allocation policy reforms, a decision analytic model was constructed to compare receipt of CMV D- with CMV D+ organ in CMV R- recipients using data from transplant registry, Medicare claims, and pharmaceutical costs. Results/UNASSIGNED:For CMV R- patients, receipt of a CMV D- organ was associated with greater average survival (14.3 vs 12.6 years), superior quality-adjusted life years (12.6 vs 9.8), and lower costs ($529 512 vs $542 963). One-way sensitivity analysis demonstrated a survival advantage for patients waiting as long as 30 months for a CMV D- kidney. Conclusions/UNASSIGNED:Altering national allocation policy to preferentially offer CMV D- organs to CMV R- recipients could improve survival and lower costs after transplant if appropriately implemented.
PMID: 34310099
ISSN: 1534-6080
CID: 5127462

The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End-Stage Liver Disease Scores and Exception Statuses

Wey, Andrew; Noreen, Samantha; Gentry, Sommer; Cafarella, Matt; Trotter, James; Salkowski, Nicholas; Segev, Dorry; Israni, Ajay; Kasiske, Bertram; Hirose, Ryutaro; Snyder, Jon
Acuity circles (AC), the new liver allocation system, was implemented on February 4, 2020. Difference-in-differences analyses estimated the effect of AC on adjusted deceased donor transplant and offer rates across Pediatric End-Stage Liver Disease (PELD) and Model for End-Stage Liver Disease (MELD) categories and types of exception statuses. The offer rates were the number of first offers, top 5 offers, and top 10 offers on the match run per person-year. Each analysis adjusted for candidate characteristics and only used active candidate time on the waiting list. The before-AC period was February 4, 2019, to February 3, 2020, and the after-AC period was February 4, 2020, to February 3, 2021. Candidates with PELD/MELD scores 29 to 32 and PELD/MELD scores 33 to 36 had higher transplant rates than candidates with PELD/MELD scores 15 to 28 after AC compared with before AC (transplant rate ratios: PELD/MELD scores 29-32, 2.34 3.324.71 ; PELD/MELD scores 33-36, 1.70 2.513.71 ). Candidates with PELD/MELD scores 29 or higher had higher offer rates than candidates with PELD/MELD scores 15 to 28, and candidates with PELD/MELD scores 29 to 32 had the largest difference (offer rate ratios [ORR]: first offers, 2.77 3.955.63 ; top 5 offers, 3.90 4.394.95 ; top 10 offers, 4.85 5.305.80 ). Candidates with exceptions had lower offer rates than candidates without exceptions for offers in the top 5 (ORR: hepatocellular carcinoma [HCC], 0.68 0.770.88 ; non-HCC, 0.73 0.810.89 ) and top 10 (ORR: HCC, 0.59 0.650.71 ; non-HCC, 0.69 0.750.81 ). Recipients with PELD/MELD scores 15 to 28 and an HCC exception received a larger proportion of donation after circulatory death (DCD) donors after AC than before AC, although the differences in the liver donor risk index were comparatively small. Thus, candidates with PELD/MELD scores 29 to 34 and no exceptions had better access to transplant after AC, and donor quality did not notably change beyond the proportion of DCD donors.
PMID: 34482614
ISSN: 1527-6473
CID: 5127612

Panel Reactive Antibody and the Association of Early Steroid Withdrawal with Kidney Transplant Outcomes

Bae, Sunjae; McAdams-DeMarco, Mara A; Massie, Allan B; Garonzik-Wang, Jacqueline M; Coresh, Josef; Segev, Dorry L
BACKGROUND:Early steroid withdrawal (ESW) is a viable maintenance immunosuppression strategy in low-risk kidney transplant recipients. A low panel reactive antibody (PRA) may indicate low-risk condition amenable to ESW. We aimed to identify the threshold value of PRA above which ESW may pose additional risk, and to compare the association of ESW with transplant outcomes across PRA strata. METHODS:We studied 121,699 deceased-donor kidney-only recipients in 2002-2017 from SRTR. Using natural splines and ESW-PRA interaction terms, we explored how the associations of ESW with transplant outcomes change with increasing PRA values, and identified a threshold value for PRA. Then, we assessed whether PRA exceeding the threshold modified the associations of ESW with 1-year acute rejection, death-censored graft failure, and death. RESULTS:The association of ESW with acute rejection exacerbated rapidly when PRA exceeded 60. Among PRA≤60 recipients, ESW was associated with a minor increase in rejection (aOR=1.001.051.10) and with a tendency of decreased graft failure (aHR=0.910.971.03). However, among PRA>60 recipients, ESW was associated with a substantial increase in rejection (aOR=1.191.271.36; interaction p<0.001) and with a tendency of increased graft failure (aHR=0.981.081.20; interaction p=0.028). The association of ESW with death was similar between PRA strata (PRA≤60, aHR=0.910.961.01; and PRA>60, aHR=0.900.991.09; interaction p=0.5). CONCLUSIONS:Our findings show that the association of ESW with transplant outcomes is less favorable in recipients with higher PRA, especially those with PRA>60, suggesting a possible role of PRA in the risk assessment for ESW.
PMCID:8490476
PMID: 33826598
ISSN: 1534-6080
CID: 5127092

Life expectancy without a transplant for status 1A liver transplant candidates

Wood, Nicholas L; VanDerwerken, Douglas N; King, Elizabeth A; Segev, Dorry L; Gentry, Sommer E
Status 1A liver transplant candidates are given the highest medical priority for the allocation of deceased donor livers. Organ Procurement and Transplantation Network (OPTN) policy requires physicians to certify that a candidate has a life expectancy without a transplant of less than 7 days for that candidate to be given status 1A. Additionally, candidates receiving status 1A must have one of six medical conditions listed in policy. Using Scientific Registry of Transplant Recipients data from all prevalent liver transplant candidates from 2010 to 2020, we used a bias-corrected Kaplan-Meier model to calculate the survival of status 1A candidates and to determine their life expectancy without a transplant. We found that status 1A candidates have a life expectancy without a transplant of 24 (95% CI 20-46) days-over three times longer than what policy requires for status 1A designation. We repeated the analysis for subgroups of status 1A candidates based on the medical conditions that grant status 1A. We found that none of these subgroups met the life expectancy requirement. Harmonizing OPTN policy with observed data would sustain the integrity of the allocation process.
PMCID:8720063
PMID: 34487636
ISSN: 1600-6143
CID: 5127622

Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series [Letter]

Connolly, Caoilfhionn M; Teles, Mayan; Frey, Sarah; Boyarsky, Brian J; Alejo, Jennifer L; Werbel, William A; Albayda, Jemima; Christopher-Stine, Lisa; Garonzik-Wang, Jacqueline; Segev, Dorry L; Paik, Julie J
PMID: 34493492
ISSN: 1468-2060
CID: 5127632

HOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV

Durand, Christine M; Florman, Sander; Motter, Jennifer D; Brown, Diane; Ostrander, Darin; Yu, Sile; Liang, Tao; Werbel, William A; Cameron, Andrew; Ottmann, Shane; Hamilton, James P; Redd, Andrew D; Bowring, Mary G; Eby, Yolanda; Fernandez, Reinaldo E; Doby, Brianna; Labo, Nazzarena; Whitby, Denise; Miley, Wendell; Friedman-Moraco, Rachel; Turgeon, Nicole; Price, Jennifer C; Chin-Hong, Peter; Stock, Peter; Stosor, Valentina; Kirchner, Varvara A; Pruett, Timothy; Wojciechowski, David; Elias, Nahel; Wolfe, Cameron; Quinn, Thomas C; Odim, Jonah; Morsheimer, Megan; Mehta, Sapna A; Rana, Meenakshi M; Huprikar, Shirish; Massie, Allan; Tobian, Aaron A R; Segev, Dorry L
Liver transplantation (LT) from donors-with-HIV to recipients-with-HIV (HIV D+/R+) is permitted under the HOPE Act. There are only three international single-case reports of HIV D+/R+ LT, each with limited follow-up. We performed a prospective multicenter pilot study comparing HIV D+/R+ to donors-without-HIV to recipients-with-HIV (HIV D-/R+) LT. We quantified patient survival, graft survival, rejection, serious adverse events (SAEs), human immunodeficiency virus (HIV) breakthrough, infections, and malignancies, using Cox and negative binomial regression with inverse probability of treatment weighting. Between March 2016-July 2019, there were 45 LTs (8 simultaneous liver-kidney) at 9 centers: 24 HIV D+/R+, 21 HIV D-/R+ (10 D- were false-positive). The median follow-up time was 23 months. Median recipient CD4 was 287 cells/µL with 100% on antiretroviral therapy; 56% were hepatitis C virus (HCV)-seropositive, 13% HCV-viremic. Weighted 1-year survival was 83.3% versus 100.0% in D+ versus D- groups (p = .04). There were no differences in one-year graft survival (96.0% vs. 100.0%), rejection (10.8% vs. 18.2%), HIV breakthrough (8% vs. 10%), or SAEs (all p > .05). HIV D+/R+ had more opportunistic infections, infectious hospitalizations, and cancer. In this multicenter pilot study of HIV D+/R+ LT, patient and graft survival were better than historical cohorts, however, a potential increase in infections and cancer merits further investigation.
PMID: 34741800
ISSN: 1600-6143
CID: 5116832

Frailty, Age, and Postdialysis Recovery Time in a Population New to Hemodialysis

Fitzpatrick, Jessica; Sozio, Stephen M; Jaar, Bernard G; Estrella, Michelle M; Segev, Dorry L; Shafi, Tariq; Monroy-Trujillo, Jose M; Parekh, Rulan S; McAdams-DeMarco, Mara A
BACKGROUND:Frailty, a phenotype characterized by decreased physiologic reserve and the inability to recover following confrontation with a stressor like hemodialysis, may help identify which patients on incident hemodialysis will experience longer postdialysis recovery times. Recovery time is associated with downstream outcomes, including quality of life and mortality. We characterized postdialysis recovery times among patients new to hemodialysis and quantified the association between frailty and hemodialysis recovery time. METHODS:Among 285 patients on hemodialysis enrolled in the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study, frailty was measured using the Fried phenotype. Self-reported recovery time was obtained by telephone interview. We estimated the association of frailty (intermediately frail and frail versus nonfrail) and postdialysis recovery time using adjusted negative binomial regression. RESULTS:Median time between dialysis initiation and study enrollment was 3.4 months (IQR, 2.7-4.9), and that between initiation and recovery time assessment was 11 months (IQR, 9.3-15). Mean age was 55 years, 24% were >65 years, and 73% were Black; 72% of individuals recovered in ≤1 hour, 20% recovered in 1-6 hours, 5% required 6-12 hours to recover, and <5% required >12 hours to recover. Those with intermediate frailty, frailty, and age ≤65 years had 2.56-fold (95% CI, 1.45 to 4.52), 1.72-fold (95% CI, 1.03 to 2.89), and 2.35-fold (95% CI, 1.44 to 3.85) risks, respectively, of longer recovery time independent of demographic characteristics, comorbidity, and dialysis-related factors. CONCLUSIONS:In adults new to hemodialysis, frailty was independently associated with prolonged postdialysis recovery. Future studies should assess the effect of frailty-targeted interventions on recovery time to improve clinical outcomes.
PMCID:8786133
PMID: 35373112
ISSN: 2641-7650
CID: 5806462